Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature by Schoser, B et al.
REVIEW Open Access
Maximum inspiratory pressure as a
clinically meaningful trial endpoint for
neuromuscular diseases: a comprehensive
review of the literature
Benedikt Schoser1*, Edward Fong2, Tarekegn Geberhiwot3, Derralynn Hughes4, John T. Kissel5, Shyam C. Madathil6,
David Orlikowski7, Michael I. Polkey8, Mark Roberts9, Harm A. W. M. Tiddens10 and Peter Young11
Abstract
Respiratory muscle strength is a proven predictor of long-term outcome of neuromuscular disease (NMD), including
amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy. Maximal inspiratory pressure
(MIP), a sensitive measure of respiratory muscle strength, one of several useful tests of respiratory muscle strength, is
gaining interest as a therapeutic clinical trial endpoint for NMD. In this comprehensive review we investigate the use of
MIP as a measure of respiratory muscle strength in clinical trials of therapeutics targeting respiratory muscle, examine
the correlation of MIP with survival, quality of life, and other measures of pulmonary function, and outline the role of
MIP as a clinically significantly meaningful outcome measure. Our analysis supports the utility of MIP for the
early evaluation of respiratory muscle strength, especially of the diaphragm, in patients with NMD and as a
surrogate endpoint in clinical trials of therapies for NMD.
Keywords: Maximum inspiratory pressure, Neuromuscular disease, Respiratory failure, Endpoint, Survival,
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Background
Weakness of the respiratory muscles is especially com-
mon among patients who have an acute or chronic
neuromuscular disease (NMD), including amyotrophic
lateral sclerosis (ALS), Guillain-Barré syndrome, spinal
muscular atrophy, myotonic dystrophy type 1, Duchenne
and other muscular dystrophies, and Pompe disease [1–3].
In patients with a NMD, irrespective of age, pathophysio-
logical mechanisms that lead to the development of re-
spiratory failure frequently include progressive weakness
in the inspiratory muscles, predominantly the diaphragm,
as indicated by respiratory patterns with low tidal volumes
[4, 5]. However, the etiology of respiratory dysfunction
can vary somewhat between different conditions [6–10].
NMD may impact different facets of respiratory
muscle function (inspiratory, expiratory extrathoracic
airways) to different extents. While expiratory muscle
weakness is associated with ineffective cough, inspiratory
muscle weakness causes dyspnea and/or nocturnal al-
veolar hypoventilation [4]. Dyspnea, which results in an
increased sense of effort, is a subjective sensation of
breathing discomfort, likened to being smothered or
suffocated. Nocturnal hypoventilation disrupts normal
sleep architecture, initially in REM sleep leading to
excessive daytime fatigue and morning headaches due
to hypercapnia [11, 12]. Other symptoms of nocturnal
hypoventilation, include insomnia, hypersomnolence,
or impaired cognition. In patients with NMD,
hypoventilation during REM sleep may be an early
marker of the functional impact of diaphragm weak-
ness [12]. Lastly, expiratory muscle weakness leads to
ineffective clearance of airway secretions, and depend-
ing on the severity of the muscle weakness, these pa-
tients are thus at a higher risk for aspiration (more
so since such patients have concomitant swallowing
difficulties), bronchitis, and pneumonia [3, 11].
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The symptoms of respiratory muscle weakness can in-
fringe significantly on daily activities (eg, walking and
eating) and quality of life (QoL) of patients with NMD.
Respiratory muscle weakness ultimately leads to respira-
tory failure and early mortality [13, 14] or the need for
noninvasive or invasive mechanical ventilation to pro-
long survival [3, 13, 15–18]. Indeed, respiratory failure
secondary to muscle weakness is a common cause of
premature death in NMD [19]. It is, therefore, critical
that patients with NMD are regularly monitored (includ-
ing for measures of respiratory muscle strength and
function, cough, and swallowing [20, 21]) and subse-
quently managed accordingly.
Maximal inspiratory pressure (MIP) and maximal ex-
piratory pressure (MEP) are direct measures of respira-
tory muscle strength and may be more sensitive in
detecting early respiratory muscle dysfunction compared
with spirometry, but MIP and MEP are not usually per-
formed on all patients referred for PFTs [22]. MIP and
MEP are noninvasive, straightforward tests in which in-
dividuals are asked to perform a forceful inspiration after
an expiration to residual volume level (in the case of
MIP) or expiration after a full inspiration to total lung
capacity (TLC; in the case of MEP) with an open glottis
against an occluded mouthpiece [5, 22, 23]; the tests are
generally practical in individuals older than 6 or 7 years
of age. They are indicated if muscle weakness could be
contributing to abnormal spirometry test results, such as
a low vital capacity (VC) [22]. MIP is a measure of global
inspiratory muscle strength and therefore has a close rela-
tionship with diaphragmatic strength, since the diaphragm
is the major inspiratory muscle; MEP is generated through
the abdominal and intercostal muscles [23–26].
Some debate exists about a “normal” value of MIP and
MEP, and different cut-off points for percentages of pre-
dicted values have been recommended, not taking into
consideration any adjustments other than gender; a recent
study [27] has recommended using more ‘cautious’ refer-
ence equations. A 2009-update [22] of the statement on
respiratory muscle testing by the American Thoracic Soci-
ety and the European Respiratory Society [23] on the as-
sessment of MRPs, provides more exact estimates for
normal values of MIP and MEP and recommends the use
of a flanged mouthpiece for the measurements. Further-
more, low MIPs can sometimes be difficult to interpret in
patients with advanced illness because exertion of max-
imal effort is a challenge for these patients.
Together, MIP and MEP measurements can accurately
assess respiratory muscle weakness, and MIP may even
predict diaphragm weakness before a significant change
in spirometry endpoints (eg, forced vital capacity [FVC])
[28]. However, despite the potential advantages of MIP
and MEP, respiratory muscle function should be evalu-
ated with the complete array of widely available lung
volume and pressure measurements, rather than relying
upon individual measurements used in isolation [29].
Given that respiratory muscle dysfunction—especially
that of the diaphragm—is common to NMDs, then
measurement of respiratory muscle strength through
MIP may provide an additional meaningful endpoint in
trials of therapeutics targeting respiratory muscle in pa-
tients with NMDs. With this in mind, we examined the
use of MIP as a clinical endpoint in trials of therapeutics
and investigated the relationship of MIP values with
other parameters associated with respiratory muscle dys-
function, including survival and QoL metrics.
Methods
We conducted literature searches in multiple databases
(EMBASE, Scopus, PubMed, ProQuest, and Google
Scholar; articles published before August 2015) and in-
cluded clinical studies that used MIP as either a primary
or secondary clinical endpoint outcome measure and re-
ported a relationship between MIP and survival, QoL,
pulmonary, and/or nonpulmonary functional endpoints.
BioMarin Pharmaceutical Inc. provided funding for this
analysis and for medical writing and editorial support
during manuscript development. BioMarin Pharmaceut-
ical Inc. was not involved in the collection, analysis, or
interpretation of data. All authors had full access to
study data and were solely responsible for the decision
to submit for publication.
Search terms included the following key words: (“max-
imal inspiratory pressure” or “nasal inspiratory pressure”
or “negative inspiratory force” or “MIP” or “PImax”) AND
(“outcome” or “endpoint” or “efficacy” or “treatment ef-
fectiveness” or “sleep-disordered breathing” or “nocturnal
hypoventilation” or “mortality” or “survival” or “death”).
We initially screened literature records on the basis of title
and abstract and excluded records not meeting the inclu-
sion criteria (eg, no MIP results reported, disease and/or
natural history focused).
To identify open, ongoing clinical trials that are using
MIP as an endpoint (primary or secondary), we searched
the ClinicalTrials.gov database (www.clinicaltrials.gov).
The search was conducted on July 12, 2015; search
terms included maximal inspiratory pressure, PImax,
and negative inspiratory force.
Results
MIP as an endpoint in clinical trials
We identified 8 publications in which MIP was used as a
primary or secondary endpoint in a randomized con-
trolled trial (RCT) of a pharmacologic therapy in a broad
spectrum of conditions (Table 1) [26, 30–36]. One of
these studies was in patients with Duchenne muscular
dystrophy [36]. Across the studies, the MIP endpoint
was reported to be a sensitive and specific clinical
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measure for evaluation of the pharmacologic interven-
tions, all of which directly targeted the respiratory
musculature.
A search of the clinical trials database revealed 31
open trials where MIP was cited as either a primary or
secondary endpoint (Table 2). The trials reflected a
range of clinical conditions; approximately 1 in 3 were
in individuals with a NMD (including ALS, Duchenne
muscular dystrophy, myasthenia gravis, Pompe disease,
and X-linked myotubular myopathy). This suggests that
MIP is gaining momentum as clinical endpoint for mon-
itoring respiratory muscle function in these patients.
Relationship between MIP and survival in patients with
NMD
As noted, respiratory failure is a common cause of pre-
mature death in patients with NMD [19]. Consequently,
patients with progressive disease require frequent moni-
toring of their pulmonary function. Sensitive, noninva-
sive predictive measures are needed to quantify the risk
of mortality due to respiratory failure in these patients;
predictive measures could also quantify the potential
mortality risk benefit of a therapeutic intervention.
Studies have investigated the correlation between MIP
and survival in various conditions (Table 3) [37–51]. In
regard to NMD, the majority of data comes from pa-
tients with ALS. All ALS published studies we identified
consistently found a correlation between MIP and sur-
vival [37–41]. A cohort study in 95 patients with ALS
found a significant association between MIP and 1-year
survival (P < 0.05) [37]. The study found that, whereas a
normal (>80% predicted) supine FVC predicted a > 80%
chance of 1-year tracheostomy-free survival, a normal
MIP or MEP predicted a > 90% chance of survival. In a
second ALS study, reduced MIP predicted poor 2-years
survival. Extensively controlled for nonpulmonary factors
known to predict survival in ALS, Kaplan-Meier and re-
ceiver operating characteristic curve analysis showed that
2-years survival was more probable in patients with ini-
tially normal MIP values (P = 0.0001) compared with
patients who had initially reduced MIP (<70 cm H2O;
P < 0.05) [38]. In a third study of ALS patients (N = 21),
MIP (−60 cm H2O or less) was 100% sensitive as a
“threshold” for predicting 18-months survival, whereas
FVC (<80% of predicted) was not as sensitive for pre-
dicting survival (<80% sensitive) [39]. In a fourth study
of 53 patients with ALS, comparison of baseline data in
patients who were dead or alive at 18 months showed that
survivors had a higher mean MIP (38 ± 24% predicted)
than nonsurvivors (20 ± 18% predicted; P < 0.01). The ab-
sence of cough spikes (defined as peak flow rate transients
during voluntary cough) had no significant influence on
survival [40]. Finally, clinical results from a 5-years pro-
spective, comparative trial of patients with ALS using non-
invasive ventilation found that determinants of respiratory
function (including MIP [P = 0.0001]) were an independ-
ent predictor of 5-years survival, emphasizing the poten-
tial utility of MIP as a prognostic indicator in patients
with ALS [41].
In a further study recently published by one of the
current authors [52], multiple outcome measures were
obtained in 78 patients with ALS who were then
followed until death. Low values for MIP were highly
specific predictors of time to death or initiation of NIV;
Table 1 Completed RCTs using MIP as a clinical endpoint
Reference MIP Endpoint Treatment Group N MIP Result
Golparvar M et al., 2005 [30] Primary Progesterone administration in
adult trauma patients during
partial support ventilation
40 MIP significantly increased (P < 0.05)
3 h after administration
Gontijo-Amaral C et al., 2012 [26] Primary Oral magnesium supplementation
in adolescent cystic fibrosis patients
44 Significant increase in MIP between
intervention and placebo period (P < 0.001)
Mackersie RC et al., 1991 [31] Primary Continuous epidural or continual
IV infusions of fentanyl in patients
with multiple rib fractures
32 Significant increase in MIP in epidural
and fentanyl epidural groups compared
with pre-analgesia (P < 0.05)
Sosis M et al., 1987 [32] Primary Atracurium treatment in patients
requiring intubation
39 Significant decrease in MIP in patients
receiving atracurium compared with
placebo (P < 0.05)
Andreas S et al., 2006 [35] Primary Irbesartan treatment in COPD
patients
60 No significant difference in MIP after 4
months of treatment (P = 0.16). Reporting a
large standard deviation of MIP.
Skorodin MS et al., 1995 [33] Primary Magnesium sulphate administration
in COPD patients
72 No significant difference in MIP after 20 and
45 min of treatment (P = NS)
Weisberg J et al., 2002 [34] Primary Megestrol acetate administration
in COPD patients
128 No significant difference in MIP (P = NS).
Reporting a large standard deviation of MIP.
Buyse GM et al., 2013 [36] Secondary Idebenone treatment in Duchenne
muscular dystrophy patients
21 MIP improved in idebenone group but
deteriorated in placebo group (P = NS)
COPD chronic obstructive pulmonary disease, IV intravenous, MIP maximum inspiratory pressure, NS not significant
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Table 2 Ongoinga clinical trials with MIP as an endpoint
NCT number Study Title Study Design Primary or Secondary
Endpoint
Estimated Study
Completion Date
Estimated
Enrollment
Neuromuscular diseases
Amyotrophic lateral sclerosis
NCT02478450 Study to Investigate the Safety of
the Transplantation (by Injection) of
Human Glial Restricted Progenitor
Cells (hGRPs; Q-Cells®) Into Subjects
With Amyotrophic Lateral Sclerosis (ALS)
Nonrandomized, open-
label, parallel group study
Secondary December 2017 12
Duchenne muscular dystrophy
NCT02310906 Phase I/II Study of SRP-4053 in
DMD Patients
Randomized, placebo-
controlled, double-blind,
parallel group study
Secondary December 2016 48
NCT01999075 Stacking Exercises Aid the Decline in FVC
and Sick Time (STEADFAST)
Randomized, single-blind,
parallel group study
Secondary August 2016 110
NCT02255552 Confirmatory Study of Eteplirsen in DMD
Patients (PROMOVI)
Nonrandomized, open-
label, parallel group study
Secondary May 2016 160
Myasthenia gravis
NCT01047761 Exercise for Stable Myasthenia Gravis Nonrandomized, open-
label, single group study
Secondary December 2015 30
Parkinson’s disease
NCT02202057 Respiratory Load Magnitude
Estimation in PD
Prospective, case control
study
Secondary August 2015 80
Pompe disease
NCT02357225 A Pilot Study of Pyridostigmine in
Pompe Disease
Nonrandomized, open-
label, single group study
Primary June 2017 16
NCT02354651 Response to Diaphragmatic Pacing in
Subjects With Pompe Disease
Prospective, observational
study
Secondary February 2017 12
NCT01924845 BMN 701 Phase 3 in rhGAA Exposed
Subjects With Late Onset Pompe
Disease (INSPIRE Study)
Nonrandomized, open-
label, single group study
Primary June 2020 50
Pulmonary hypertension
NCT02288442 Whole Muscle Exercise Training (WHOLEi
+ 12) in Pulmonary Hypertension
Randomized, single-blind,
parallel group study
Secondary September 2016 20
Sarcopenia
NCT02120586 Preventive Physiotherapy Intervention in
Elderly People With Sarcopenia
Randomized, single-blind,
parallel group study
Primary July 2015 70
X-linked myotubular myopathy
NCT02453152 Respiratory Muscle Function in Untreated
X-Linked Myotubular Myopathy (XLMTM)
Prospective, observational
study
Secondary December 2016 12
Other disorders (non-NMDs)
Back pain
NCT02429752 Low Back Pain and Breathing Pattern
Dysfunction (LBP & BPD)
Open-label, single group
study
Secondary June 2016 75
Breast disease
NCT02491762 The Effect of Breast Reconstruction
Surgery Using Tissue Expanders on
Respiratory Functions
Nonrandomized, open-
label, parallel group study
Primary August 2017 45
NCT02165696 Compression Bandaging and Manual
Lymph Drainage in Women With
Lymphedema (LYMPHATIC)
Randomized, single-blind,
parallel group study
Secondary December 2015 44
COPD
NCT01655199 Sensitivity of the Step Test to Detect
Improvement in Dyspnea Following
Bronchodilation in Patients With Chronic
Obstructive Pulmonary Disease (CODEx)
Double-blind, single
group study
Secondary July 2014 40
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Table 2 Ongoinga clinical trials with MIP as an endpoint (Continued)
NCT01903772 Effects of Inspiratory Muscle Training in
Chronic Obstructive Pulmonary Disease
(COPD) (IMTCO)
Randomized, double-
blind, parallel group
study
Secondary December 2015 72
NCT01956565 Feasibility of Inspiratory Muscle Training
in People With COPD Who Decline
Pulmonary Rehabilitation
Nonrandomized, open-
label, single group study
Secondary November 2015 20
NCT02392715 Inspiratory Muscle Training Combined
With General Exercise Training in
COPD (IMTGET)
Randomized, double-
blind, parallel group
study
Secondary October 2016 80
NCT02007772 Effectiveness of TNI vs. BiPAP in Chronic
Global Insufficiency in COPD
Patients (TIBICO)
Randomized, open-label,
crossover study
Secondary August 2015 85
NCT01582958 The Effect of OMT on Patients With
COPD: Correlating Pulmonary Function
Tests With Biochemical Alterations
Randomized, single-blind,
parallel group study
Primary August 2015 60
NCT01037387 Effect of Noninvasive Ventilation on
Physical Activity and Inflammation in
COPD Patients
Randomized, open-label,
parallel group study
Secondary June 2016 50
COPD or asthma
NCT02233114 Do Yogic Exercises (12 weeks) Increase
Respiratory Function in Patients with
Obstructive Lung Diseases?
Randomized, single-blind,
parallel group study
Secondary December 2017 40
Chronic respiratory insufficiency
NCT01458314 Non Invasive Mechanical Ventilation in
Chronic Respiratory Insufficiency Patients
During Rehabilitation
Randomized, open-label,
parallel group study
Secondary June 2015 50
Chronic respiratory failure
NCT00994552 Comparison of Pressure Support and
Pressure Control Ventilation in Chronic
Respiratory Failure
Randomized, single-blind
crossover study
Secondary April 2010 20
Congenital heart disease
NCT02438293 The Impact of Rhinovirus Infections in
Paediatric Cardiac Surgery’ (RISK)
Prospective, observational
study
Secondary June 2016 250
Intraventricular hemorrhage
NCT02231411 Neonatal Resuscitation With Intact
Cord (NRIC)
Randomized, single-blind,
parallel group study
Secondary August 2016 150
Lung cancer
NCT02493114 Functional Status in Patients Undergoing
Curative Treatment for Lung Cancer
Prospective, observational
study
Secondary November 2017 80
Mechanically ventilated patients
NCT02003053 A Randomized, Controlled Trial of
Inspiratory Muscle Training (IMT) in the
ICU and CCU
Randomized, single-blind,
parallel group study
Primary September 2015 40
Obstructive sleep apnea
NCT02259660 Airway Muscle Training for Obstructive
Sleep Apnea (OSA)
Randomized, double-
blind, parallel group
study
Secondary September 2016 60
Stroke
NCT02400138 Home-based Respiratory Training
After Stroke
Randomized, double-blind,
parallel group study
Primary November 2016 20
aClinical trials in progress as of October 31st, 2015
BiPAP biphasic positive airway pressure, CCU critical care unit, COPD chronic obstructive pulmonary disease, DMD Duchenne muscular dystrophy,
FVC forced vital capacity, ICU intensive care unit, MIP maximum inspiratory pressure, OMT osteopathic manipulative treatment, PD Parkinson’s
disease, TNI therapy with nasal insufflation
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Table 3 Summary of studies investigating the correlation between MIP and survival
Reference Therapy Area/
Population
Study Type N MIP and Survival
Correlation between MIP and survival
Schmidt EP et al., 2006 [37] ALS Cohort study 95 MIP was an important predictor of 1-year
survival (P < 0.05) after controlling for
nonpulmonary factors known to predict
survival in ALS
Baumann F et al., 2010 [38] ALS Cohort study 80 MIP was significantly associated with survival
(P < 0.05); survival time was increased in
patients with normal MIP
Gay PC et al., 1991 [39] ALS Prospective study 21 MIP was 100% sensitive for predicting
18-months survival (r = 0.57; P < 0.007)
Chaudri MB et al., 2002 [40] MND (ALS) Single-center
cohort study
53 Survivors had a higher percentage of
predicted MIP than nonsurvivors
(37.83 ± 24.32% vs 20.13 ± 18.43%; P < 0.01)
Lopes Almeida JP, et al., 2012 [41] ALS Prospective,
comparative study
60 There was a significant correlation between
MIP and 5-years survival (P = 0.02) in patients
with ALS using NIV
Benzo R et al., 2013 [42] COPD Analysis of clinical
data from NETT
1218 Decrease in MIP > 11 cm H2O was a predictor
of 1-year mortality (OR, 2.19; P = 0.0217)
Gray-Donald K et al., 1996 [43] COPD 3 to 5-years follow-
up of a double-
blind RCT
348 Low MIP was a significant independent
predictor of respiratory (HR, 0.64; 95% CI,
0.44–0.95) and all-cause mortality (HR, 0.67;
95% CI, 0.47–0.95)
Schols AMWJ et al., 1998 [44] COPD RCT 203 Improvement in MIP during rehabilitation
decreased the risk of death
Hodgev VA et al., 2006 [45] COPD Prospective cohort
study
63 A Cox proportional hazards analysis showed
that MIP was a significant predictor of mortality
(r = 0.91; 95% CI, 0.85–0.97; P = 0.005)
Meyer FJ et al., 2001 [47] Heart failure Prospective study 244 In a univariate Cox regression analysis, MIP was
found to be a significant prognostic indicator
of survival (P = 0.001)
Frankenstein L et al., 2009 [48] Heart failure Prospective,
observational study
686 MIP was identified as a significant predictor of
survival by univariate analysis; survivors had a
significantly higher MIP and percentage of
predicted MIP than nonsurvivors
Ionescu AA et al., 1998 [49] Cystic fibrosis Single-center study 49 Mean % predicted MIP (SD) for survivors was
85.5% (28.4) compared with 64.1% (23.9) for
nonsurvivors
Marroni CA et al., 2014 [50] Liver cirrhosis Prospective cohort
study
86 Sixty-two percent of patients with MIP < −70 cm
H2O survived compared with 93% of patients with
MIP > −70 cm H2O (P = 0.0001)
Budweiser S et al., 2007 [46] Chronic hypercapnic
respiratory failure
Cohort study 464 MIP was a significant predictor of long-term
survival; according to stepwise multivariate Cox
regression analysis, P0.1/MIP was identified as an
independent predictor of survival (P < 0.05)
van der Palen J et al., 2004 [51] Elderly with a mean
age of 72.5 years
Cohort study 3839 Subjects in the lowest quintile of MIP had a
1.5-fold increased risk of cardiovascular-related
death (HR, 1.54; 95% CI, 1.09–2.15) after
adjustment for nonpulmonary function covariates
No correlation between MIP and survival
Nizet TAC et al., 2005 [58] Chronic hypercapnic
COPD
Prospective, single-
center study
47 No significant association
Frankenstein L et al., 2008 [54] CHF Prospective, single-
arm study
158 No significant association
Habedank D et al., 2013 [55] CHF Single-center study 249 No significant association
Schoser et al. Orphanet Journal of Rare Diseases  (2017) 12:52 Page 6 of 12
conversely, while VC was also a specific predictor, the
cut points suggested by ROC analysis were >80% of nor-
mal at all time points except for 3 months mortality pre-
diction (when it was 78%), suggesting that a normal VC
was of limited practical value. However, a small (N = 18)
study of MIP and survival in patients with Duchenne mus-
cular dystrophy [53] did not find a predictive association. It
should be noted that participants had extremely low values
of MIP and VC at the start of study and that the analysis
did not include the use of noninvasive ventilation.
Some studies in non-neuromuscular diseases—chronic
obstructive pulmonary disease (COPD) [42–45], cystic
fibrosis [49], liver cirrhosis [50], hypercapnic respiratory
failure [46], and congestive heart failure [47, 48, 51]—sug-
gest that MIP may correlate with survival, while others re-
port no correlation [54–59] (Table 3), indicating that
further investigation is needed. We also caution that in
non-neuromuscular disease states, a reduced MIP may
simply reflect generalized cachexia, which is a recognized
marker of a poor prognosis and hyperinflation [60] in pul-
monary disease.
Relationship between MIP and QoL in patients with NMD
As NMD pathology progresses and patients develop re-
spiratory dysfunction, QoL (with respect to a patient’s
physical, emotional, social functioning, mental health,
bodily pain, endurance, and general health perceptions)
and sleep can be severely impacted [18, 61, 62]. The
relationship between changes in MIP and QoL in
NMD was addressed in 2 studies from our literature
search: one in ALS [18] and one in patients with
post-poliomyelitis syndrome [63].
Bourke et al. evaluated the impact of noninvasive
intervention on QoL in 22 patients with ALS using the
36-Item Short Form (SF-36) and the National Center for
Health Statistics General Well-Being Schedule and con-
cluded that respiratory muscle weakness had an impact
on QoL [18]. Overall, the researchers found that patients
with ALS with significantly lower QoL displayed lower
MIP values. Lower MIP values corresponded with lower
SF-36 scores in all domains except the pain and physical
components [18]. Instruments specifically assessing re-
spiratory and sleep-related problems (eg, the Epworth
Sleepiness Scale [ESS]) were most sensitive to changes
in MIP [18]. In this regard, ESS scores were highest
(indicating sleep disruption) in patients with MIP values
below 50% and were lowest in patients with MIP values
above 50% (10.3 and 4.8%, respectively; P = 0.01) [18].
Similar to the findings of Bourke et al., a cross-sectional
study of 52 patients with post-poliomyelitis syndrome ob-
served a significant correlation between MIP and both the
fatigue severity scale and the Multidimensional Fatigue
Inventory (MFI) (r = −0.31 and r = −0.41, respectively;
P < 0.05). The researchers also found that a 10-unit de-
cline for MIP (% predicted) corresponded to patients
scoring a 0.3-unit increase on the General Fatigue di-
mension of the MFI scale [63]. This dimension of the
MFI scale ranges from 4 to 20, with higher scores indi-
cating more severe fatigue.
Relationship between MIP and spirometry in patients
with NMD
In patients with NMD whose lungs are restricted from
fully expanding, spirometry is widely used to assess re-
spiratory muscle function. Patients performing spirometry
are asked to take a maximal inspiration and perform a
FVC maneuver. A drop of more than 20% of FVC going
from the upright to the supine position is a useful diag-
nostic of diaphragmatic weakness [64]. FVC, however, has
a curvilinear relationship with respiratory muscle strength,
and substantial weakness may be present while FVC is still
within the normal range [65].
Lung volume measurements are sometimes performed
in patients with NMD, including TLC and functional re-
sidual capacity (FRC; defined as the amount of air in the
lungs following normal expiration). In these patients,
when inspiratory muscles are weak, then a maximum ef-
fort may be insufficient to fully expand the lungs, and
the TLC and FRC will be reduced [22, 24]. Similarly, if
abdominal muscle strength is impaired, residual volume
may also be elevated [22].
When carbon monoxide gas transfer is measured, the
classic picture of respiratory muscle weakness is a low
diffusion capacity (DLCO) and an elevated transfer coeffi-
cient (KCO). However, a study in patients with NMDs
showed that the rise in KCO was often less than
Table 3 Summary of studies investigating the correlation between MIP and survival (Continued)
Hui D et al., 2014 [56] Advanced cancer Prospective, single-
center study
222 No significant association
White AC et al., 2005 [59] Hematopoietic stem
cell transplantation
Prospective
observational study
56 No significant association
Jackson M et al., 1994 [57] Patients with a
thoracoplasty for
tuberculosis
Single-center study 32 No significant association
ALS amyotrophic lateral sclerosis, CHF congestive heart failure, CI confidence interval, COPD chronic obstructive pulmonary disease, HR hazard ratio, MIP maximum
inspiratory pressure, MND motor neurone disease, NETT National Emphysema Treatment Trial, NIV noninvasive ventilation, OR odds ratio, P0.1 mouth occlusion
pressure, RCT randomized controlled trial, SD standard deviation
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expected; in patients with combined inspiratory and ex-
piratory muscle weakness, a reduced value was observed
[66]. The results demonstrated the limitations of using
KCO in the diagnosis of respiratory muscle weakness.
Gas exchange anomalies can also be multifactorial in
their origin, for example, mechanical problems and air-
way obstructions can affect results [67].
While the above discussed spirometry tests have util-
ity, they can be considered insensitive measures of re-
spiratory muscle function since a significant reduction in
lung volume may not be observed until severe impair-
ment of respiratory muscles has occurred [67]. Also,
other factors such as airway obstruction due to asthma
or lower airway obstruction may affect the reliability of
some spirometry results [5, 68–70]. Consistent with
these limitations, when measured within 30 days of the
need for tracheostomy in a clinical trial of therapeutics
for ALS [71], VC was ≥ 60% predicted in 14% of ALS pa-
tients (n = 50).
MIP has physiological relationships with spirometry
endpoints [65]. Specifically, in patients with a NMD, sev-
eral studies have shown a correlation between MIP and
FVC. In a study of patients with Duchenne muscular
dystrophy, a significant 1-year decrease in MIP was asso-
ciated with decreases in FVC, FEV1 (defined as forced
expiratory volume in 1 sec), and peak expiratory flow
rate (P < 0.05 for all measures) [72]. Similarly, Schmidt
et al. found a significant association between MIP and
upright FVC in a 1-year cohort study of 95 patients with
ALS [37].
Also, the LOTS study investigated the effect of alglu-
cosidase alfa treatment in patients with late-onset
Pompe disease [73]. Patients who entered an open-label
extension phase of this trial showed additional improve-
ment in MIP but a slight decline in FVC from week 78
through week 104; a statistical correlation however was
not reported [74]. Finally, a RCT conducted by Cheah et
al. to assess the effects of a 12-weeks inspiratory muscle
training program in patients with ALS found that
improvements in MIP reflected improvements in FVC
and TLC [75]. In 3 RCTs where MIP improvements
were observed following pharmacologic treatment in
patients with non-neuromuscular diseases, these values
also correlated with improvements in other pulmonary
measures, including FVC (as well as airway resistance
and MEP) [26, 30, 31].
Additional non-RCT studies supporting a correlation
between MIP and spirometry in patients with NMDs
have also been performed in patients with Pompe dis-
ease, Guillain-Barré syndrome, and myasthenia gravis
[70, 74, 76, 77]. In a prospective cohort study in patients
with Pompe disease, MIP and MEP were both strongly
correlated with VC (r = 0.75 and r = 0.79, respectively)
[76]. Follow-up data (median 1.6 years) showed that VC
(upright or supine) deteriorated by 0.9–1.2% points per
year, respectively, with deteriorations in MIP and MEP of
3.2% (P = 0.018) and 3.8% (P < 0.01) per year, respectively
[76]. In a study of patients with respiratory muscle weak-
ness and one study of multiple NMDs, MIP was found to
significantly correlate with FRC (r = 0.62; P < 0.001) and
VC (r = 0.88; P < 0.001) [77]. A direct investigation of
the sensitivity of MIP versus VC in patients with
either Guillain-Barré syndrome (n = 40) or myasthenia
gravis (n = 44) found a linear relationship between the
2 measurements [70].
Taken together, these studies demonstrate that in pa-
tients with NMD there is a correlation between MIP and
FVC, FEV1, body plethysmography, and diffusion tech-
niques. In addition, MIP could have utility as a clinical
endpoint in therapeutic trials for the treatment of neuro-
muscular diseases. A recent study in ALS patients with
progressive respiratory dysfunction provided indirect
evidence that reductions in MIP occur prior to reductions
in FVC [28]. In patients with ALS, clinicians detected the
progression of respiratory dysfunction 6.5 months earlier
when monitoring MIP compared with FVC alone. This in-
dicates that MIP may be a more sensitive measure of re-
spiratory disease progression, supporting its potential
utility as a clinical trial endpoint.
Relationship between MIP and nonpulmonary measures
in patients with NMD
Walking tests are an integrated assessment of cardiac,
pulmonary, circulatory, and muscular capacity, providing
a measure of the functional exercise level required to
undertake daily physical activities. Neuromuscular and
pulmonary studies investigating the impact of MIP on
ambulatory measures showed that, in some cases, im-
provements in MIP coincided with improvements in
walking tests [25, 34, 54, 74, 75, 78–85]. Two studies
were identified comparing MIP with walking tests: one
in Pompe disease and one in ALS. The study of patients
with Pompe disease [74] receiving enzyme replacement
therapy found that changes in the 6-min walk test
(6MWT) were directionally consistent with changes in
MIP. However, no such association was found in the
study of patients with ALS [75].
Discussion
Since the development of respiratory failure is a significant
predictor of early death, many clinical trials currently em-
ploy established spirometry endpoints, including FVC, to
evaluate an intervention in patients with NMD. However,
as these endpoints are measures of overall pulmonary
function, they may also be affected by factors that are in-
dependent of respiratory muscle dysfunction. Given that
respiratory muscle dysfunction is common in neuromus-
cular diseases, directly evaluating diaphragm muscle
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strength by measuring MIP could complement spiromet-
ric endpoints in studies of patients with these diseases. In
this regard, our analysis identified the use of MIP as an
endpoint in several RCTs of pharmacologic therapies
across a spectrum of diseases [26, 30–36]. These trials
found MIP to be a clinically relevant outcome measure in
chronic diseases when respiratory failure is secondary to
respiratory muscle weakness.
However, diminished MIP does not always reliably
confirm inspiratory muscle weakness. This is due to
MIP measurement errors, including submaximal effort,
poor transmission of intrathoracic pressure to the extra-
thoracic airways [22] as well as NMD patient-device
interface issues or additional chest wall alterations [75].
For example, interface issues occur in patients with
NMD with bulbar and/or facial weakness who have diffi-
culty making a good lip seal. However, with proper train-
ing, MIP can be a reliable, accurate, and an early
indicator of respiratory muscle weakness, which is more
independent of existing lung abnormalities than FVC
and VC [22, 86–88]. In this respect, a number of on-
going and planned clinical trials are evaluating MIP as a
primary or secondary endpoint in studies of patients
with NMDs (Table 2).
In order to further validate MIP as a clinical endpoint
in studies of patients with NMD, it is important to es-
tablish whether MIP is associated with clinically mean-
ingful outcomes, such as time to ventilator support or
even overall survival. In this regard, our analysis found
that MIP was correlated with survival in patients with
some NMDs (particularly ALS) and that MIP made an
important contribution to predictive multivariate model-
ing analyses [37–41]. Studies in patients with ALS con-
sistently found that higher MIP values were associated
with increased survival. One study found MIP to be
100% sensitive as a threshold for predicting survival in
patients with ALS at 18-months follow-up [39]. Add-
itionally, clinical studies that extended up to 5 years
found a positive association between MIP and survival
in a number of therapy areas [41, 43].
Our analysis also suggests that MIP may be reflective
of challenges faced by patients with NMD in their daily
life. Two studies conducted in patients with NMD found
that MIP correlated with improvements in QoL scores,
including domains relating to sleep and fatigue [18, 63].
Another study in patients with Pompe disease indicated
that MIP was significantly correlated with the 6MWT
[74, 85]. These findings suggest that MIP may have use-
ful long-term clinical relevance in patients with NMDs.
Furthermore, in the majority of NMD studies examined,
there was a strong correlation between MIP with other
pulmonary measures, including with FVC, FEV1, VC,
and TLC [37, 72, 74–76]. In addition, there is some evi-
dence to indicate that, when respiratory muscle function
starts to deteriorate, MIP measurements may decrease
earlier than other pulmonary measures, suggesting that
MIP may be a more sensitive method for monitoring pa-
tients [28]. In ALS patients, for example, reduced in-
spiratory muscle strength (MIP) was noted after
cessation of inspiratory muscle training despite other
pulmonary measures remaining unchanged [75].
In addition to MIP, the SNIP test can be used to meas-
ure respiratory muscle strength in the clinic. Like MIP,
SNIP also reflects esophageal pressure in most patients,
but a minority of patients will obtain substantially larger
values on one test than the other [89]. SNIP is measured
by plugging one nostril while the other is free; this test
is useful when there is facial weakness or dental mal-
occlusion, which may make the MIP test difficult [5]. It
is a reproducible and accurate measure of inspiratory
muscle strength [90] and can be reliably performed and
used even in infants and children [91]. SNIP has been
used to monitor respiratory muscle strength in patients
with NMD [92, 93]. However, it has limitations such as
underestimating esophageal pressure swing in patients
with severe nasal obstruction or airway diseases such as
COPD, which impair pressure transmission [94–96].
Additionally, SNIP measures a fast contraction of in-
spiratory muscles, whereas MIP measures a sustained
isometric contraction [95]. As isometric muscle force of
limb muscles is a standard measure of muscle function,
it has been argued that in some NMDs, such as ALS,
MIP might provide a more meaningful measurement of
respiratory muscle function than SNIP [95].
Our analysis of MIP as a clinical outcome measure in pa-
tients with NMDs is limited by the small number of pub-
lished studies and small sample sizes. However, the fact
that there are currently 12 registered trials in patients with
NMD where MIP is being used as a clinical endpoint sug-
gests that specific measurements of ventilatory function
are important outcomes in these patient cohorts. These tri-
als will provide further evidence of the reliability and utility
of MIP. Additionally, MIP may prove to be more sensitive
than FVC for assessing ventilatory dysfunction since spiro-
metric pulmonary function tests are influenced by other
factors (including scoliosis and other lung diseases), which
may affect the reliability of results [5, 68–70].
Conclusions
In summary, our analysis supports the use of MIP as a
diagnostic of respiratory muscle dysfunction in patients
with chronic NMDs and its utility as an endpoint in fu-
ture clinical trials which monitor the efficacy of thera-
peutics in neuromuscular diseases. Through continued
investigation of MIP in NMD, clinicians and researchers
will gain a comprehensive understanding of the role of
this direct measure of respiratory muscle strength in
clinical practice.
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